EVANSTON, Ill. -- Universal hospital surveillance of methicillin-resistant Staphylococcus aureus (MRSA) using a rapid molecular diagnostic test is effective in significantly reducing MRSA disease, according to research published in the Annals of Internal Medicine by a team of Evanston Northwestern Healthcare (ENH) researchers. The ENH study, "Universal Surveillance for [MRSA] in 3 Affiliated Hospitals," appears in the March 18, 2008 issue of the American College of Physicians journal, Annals of Internal Medicine.
Evanston Northwestern Healthcare became the first healthcare provider in the United States to launch a comprehensive, universal MRSA surveillance program, swabbing all inpatients at its three hospitals (Evanston, Glenbrook and Highland Park) for the MRSA bacteria, a potentially fatal infection that does not respond to common antibiotics and is a significant cause of hospital-acquired infections.
"The goal of the program was always to reduce the risk of MRSA infection to patients cared for by ENH. We achieved all our benchmarks by the end of the program's first year," said Lance R. Peterson, MD, FASCP, epidemiologist and a founder of the MRSA program at Evanston Northwestern Healthcare. "The program we began in August of 2005 had a major patient safety impact for all our patients and demonstrated that a comprehensive effort to reduce MRSA infection can be accomplished in the United States."
At its three hospitals, ENH was able to reduce MRSA infection rates by 70 percent in less than two years. ENH also demonstrated a systemwide compliance with admission testing of more than 90 percent. The program lowered the risk of other patients and staff becoming carriers of MRSA; and becoming a MRSA carrier is the highest risk for eventually developing an infection with this bacteria.
A new molecular screening test that was approved for patient use shortly before the program began facilitated the ENH initiative. This test shortens the testing time for finding MRSA to under two hours and permits the detection of MRSA carriers the day of admission so that they could be appropriately cared for to reduce spread to others. Peterson stated that, "Reducing spread of MRSA to new patients within the healthcare system is critical to eliminating this infection and the ENH program encompassing over 70,000 patients shows that such a patient-oriented program can be successful."
ENH researchers defined MRSA infection as a combination of all MRSA bloodstream, respiratory, urinary tract, and surgical site infections that occurred during admission and 30 days after discharge. The study concluded that universal screening was associated with a large reduction in MRSA disease during those timeframes.
The study examined the effect of two expanded MRSA surveillance interventions. It compared MRSA rates during and after hospital admission in three consecutive periods: baseline (12 months), MRSA surveillance for all admissions to the intensive care unit (12 months), and universal MRSA surveillance for all hospital admissions (21 months). Only universal surveillance was successful in significantly reducing healthcare-associated MRSA infections.
The screening program involved performing nasal swabs on all inpatients for colonization during the hospital admission process. Electronic medical record and same-day molecular diagnostic testing facilitated quick assessment for MRSA colonization and allowed hospital staff to promptly identify, isolate and treat MRSA-positive patients.
Peterson says, "Our program has successfully prevented nasal colonization of patients coming to ENH for their care. We want people to come here for their healthcare and not go home with something unexpected that will later cause an infection -- and the program is successful in doing just that."
Source: Evanston Northwestern Healthcare
Â
Â
Â
  Â
Â
Â
Â
  Â
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.